Trial Outcomes & Findings for Buprenorphine Plus Baclofen to Increase Analgesia in Healthy Volunteers (NCT NCT04251819)
NCT ID: NCT04251819
Last Updated: 2026-01-07
Results Overview
Pain threshold refers to the intensity at which a stimulus is first perceived as painful. Heat stimuli will be delivered using a computer-controlled thermal stimulation system with a 30 millimeter X 30 millimeter probe. From a baseline of 32 degrees Celsius, the probe temperature will increase at a rate of .5 degrees Celsius/second until the participant responds by pressing a button on a handheld device. For heat pain threshold, participants will be instructed to press the button when the sensation "first becomes painful" Pain rating scores will be reflected in scores of 0-100, 0 being the least amount of pain and 100 being the most amount of pain.
TERMINATED
PHASE2/PHASE3
19 participants
Baseline
2026-01-07
Participant Flow
Participant milestones
| Measure |
Placebo
Participants randomized to this arm will receive Placebo.
|
Baclofen 5mg
Participants randomized to this arm will receive 5 mg of Baclofen.
|
Baclofen 10mg
Participants randomized to this arm will receive 10 mg of Baclofen.
|
|---|---|---|---|
|
Overall Study
STARTED
|
6
|
8
|
5
|
|
Overall Study
COMPLETED
|
6
|
8
|
5
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Buprenorphine Plus Baclofen to Increase Analgesia in Healthy Volunteers
Baseline characteristics by cohort
| Measure |
Placebo
n=6 Participants
Participants randomized to this arm will receive Placebo.
|
Baclofen 5mg
n=8 Participants
Participants randomized to this arm will receive 5 mg of Baclofen.
|
Baclofen 10mg
n=5 Participants
Participants randomized to this arm will receive 10 mg of Baclofen.
|
Total
n=38 Participants
Total of all reporting groups
|
|---|---|---|---|---|
|
Age, Continuous
|
27.17 years
STANDARD_DEVIATION 12.58 • n=6 Participants
|
36.63 years
STANDARD_DEVIATION 11.89 • n=8 Participants
|
22.8 years
STANDARD_DEVIATION 2.59 • n=5 Participants
|
29.58 years
STANDARD_DEVIATION 11.46 • n=19 Participants
|
|
Sex: Female, Male
Female
|
2 Participants
n=6 Participants
|
8 Participants
n=8 Participants
|
2 Participants
n=5 Participants
|
12 Participants
n=19 Participants
|
|
Sex: Female, Male
Male
|
4 Participants
n=6 Participants
|
0 Participants
n=8 Participants
|
3 Participants
n=5 Participants
|
7 Participants
n=19 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
1 Participants
n=6 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=5 Participants
|
1 Participants
n=19 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=6 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=19 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=6 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=19 Participants
|
|
Race (NIH/OMB)
Black or African American
|
0 Participants
n=6 Participants
|
2 Participants
n=8 Participants
|
0 Participants
n=5 Participants
|
2 Participants
n=19 Participants
|
|
Race (NIH/OMB)
White
|
5 Participants
n=6 Participants
|
4 Participants
n=8 Participants
|
2 Participants
n=5 Participants
|
11 Participants
n=19 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=6 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=19 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=6 Participants
|
2 Participants
n=8 Participants
|
3 Participants
n=5 Participants
|
5 Participants
n=19 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
0 Participants
n=6 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=19 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
6 Participants
n=6 Participants
|
8 Participants
n=8 Participants
|
5 Participants
n=5 Participants
|
19 Participants
n=19 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=6 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=19 Participants
|
|
Region of Enrollment
United States
|
6 Participants
n=6 Participants
|
8 Participants
n=8 Participants
|
5 Participants
n=5 Participants
|
19 Participants
n=19 Participants
|
PRIMARY outcome
Timeframe: BaselinePain threshold refers to the intensity at which a stimulus is first perceived as painful. Heat stimuli will be delivered using a computer-controlled thermal stimulation system with a 30 millimeter X 30 millimeter probe. From a baseline of 32 degrees Celsius, the probe temperature will increase at a rate of .5 degrees Celsius/second until the participant responds by pressing a button on a handheld device. For heat pain threshold, participants will be instructed to press the button when the sensation "first becomes painful" Pain rating scores will be reflected in scores of 0-100, 0 being the least amount of pain and 100 being the most amount of pain.
Outcome measures
| Measure |
Baclofen 10mg
n=5 Participants
Participants randomized to this arm will receive 10 mg of Baclofen.
Baclofen 10mg: Participants will receive 10mg of baclofen in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
|
Baclofen 5mg
n=8 Participants
Participants randomized to this arm will receive 5 mg of Baclofen.
Baclofen 5 mg: Participants will receive 5mg of baclofen in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
|
Placebo
n=6 Participants
Participants randomized to this arm will receive Placebo.
Placebos: Participants will receive placebo in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
|
|---|---|---|---|
|
Pain Threshold
|
43.56 Degrees Celsius
Standard Deviation 3.77
|
45.11 Degrees Celsius
Standard Deviation 3.04
|
44.62 Degrees Celsius
Standard Deviation 2.13
|
PRIMARY outcome
Timeframe: 1.5 hours post-drug administration during session 2, occurs 7 ± 2 days after baseline visitPopulation: Data were missing.
Pain threshold refers to the intensity at which a stimulus is first perceived as painful. Heat stimuli will be delivered using a computer-controlled thermal stimulation system with a 30 millimeter X 30 millimeter probe. From a baseline of 32 degrees Celsius, the probe temperature will increase at a rate of .5 degrees Celsius/second until the participant responds by pressing a button on a handheld device. For heat pain threshold, participants will be instructed to press the button when the sensation "first becomes painful" Pain rating scores will be reflected in scores of 0-100, 0 being the least amount of pain and 100 being the most amount of pain.
Outcome measures
| Measure |
Baclofen 10mg
n=5 Participants
Participants randomized to this arm will receive 10 mg of Baclofen.
Baclofen 10mg: Participants will receive 10mg of baclofen in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
|
Baclofen 5mg
n=8 Participants
Participants randomized to this arm will receive 5 mg of Baclofen.
Baclofen 5 mg: Participants will receive 5mg of baclofen in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
|
Placebo
n=5 Participants
Participants randomized to this arm will receive Placebo.
Placebos: Participants will receive placebo in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
|
|---|---|---|---|
|
Pain Threshold
|
42.06 Degrees Celsius
Standard Deviation 3.14
|
43.95 Degrees Celsius
Standard Deviation 2.70
|
43.82 Degrees Celsius
Standard Deviation 2.46
|
PRIMARY outcome
Timeframe: BaselinePain tolerance refers to the maximum amount of pain produced by a stimulus that a person is able/willing to tolerate. Heat stimuli will again be delivered using the computer-controlled thermal stimulation system. From a baseline of 32 degrees Celsius, the probe temperature will increase at a rate of .5 degrees Celsius/second until the participant responds by pressing a button on a handheld device. For heat pain tolerance, participants will be instructed to press the button when they are "no longer willing to tolerate" the painful sensation. Pain rating scores will be reflected in scores of 0-100, 0 being the least amount of pain and 100 being the most amount of pain.
Outcome measures
| Measure |
Baclofen 10mg
n=5 Participants
Participants randomized to this arm will receive 10 mg of Baclofen.
Baclofen 10mg: Participants will receive 10mg of baclofen in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
|
Baclofen 5mg
n=8 Participants
Participants randomized to this arm will receive 5 mg of Baclofen.
Baclofen 5 mg: Participants will receive 5mg of baclofen in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
|
Placebo
n=6 Participants
Participants randomized to this arm will receive Placebo.
Placebos: Participants will receive placebo in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
|
|---|---|---|---|
|
Pain Tolerance
|
47.34 Degrees Celsius
Standard Deviation 2.11
|
46.84 Degrees Celsius
Standard Deviation 2.00
|
48.17 Degrees Celsius
Standard Deviation 1.52
|
PRIMARY outcome
Timeframe: 1.5 hours post-drug administration during session 2, occurs 7 ± 2 days after baseline visitPopulation: Data were missing.
Pain tolerance refers to the maximum amount of pain produced by a stimulus that a person is able/willing to tolerate. Heat stimuli will again be delivered using the computer-controlled thermal stimulation system. From a baseline of 32 degrees Celsius, the probe temperature will increase at a rate of .5 degrees Celsius/second until the participant responds by pressing a button on a handheld device. For heat pain tolerance, participants will be instructed to press the button when they are "no longer willing to tolerate" the painful sensation. Pain rating scores will be reflected in scores of 0-100, 0 being the least amount of pain and 100 being the most amount of pain.
Outcome measures
| Measure |
Baclofen 10mg
n=5 Participants
Participants randomized to this arm will receive 10 mg of Baclofen.
Baclofen 10mg: Participants will receive 10mg of baclofen in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
|
Baclofen 5mg
n=8 Participants
Participants randomized to this arm will receive 5 mg of Baclofen.
Baclofen 5 mg: Participants will receive 5mg of baclofen in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
|
Placebo
n=5 Participants
Participants randomized to this arm will receive Placebo.
Placebos: Participants will receive placebo in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
|
|---|---|---|---|
|
Pain Tolerance
|
46.36 Degrees Celsius
Standard Deviation 2.56
|
47.70 Degrees Celsius
Standard Deviation 2.20
|
47.84 Degrees Celsius
Standard Deviation 1.86
|
PRIMARY outcome
Timeframe: BaselinePopulation: Data were missing.
Temporal summation of pain refers to a form of endogenous pain facilitation characterized by the perception of increased pain despite constant or even reduced peripheral afferent input. Temporal summation is presumed to be the psychophysical manifestation of wind-up. Wind-up is a phenomenon where repetitive stimulation of C primary afferents at rates greater than 0.3 Hertz produces a slowly increasing response of second-order neurons in the spinal cord. Pain rating scores will be reflected in scores of 0-100, 0 being the least amount of pain and 100 being the most amount of pain.
Outcome measures
| Measure |
Baclofen 10mg
n=4 Participants
Participants randomized to this arm will receive 10 mg of Baclofen.
Baclofen 10mg: Participants will receive 10mg of baclofen in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
|
Baclofen 5mg
n=5 Participants
Participants randomized to this arm will receive 5 mg of Baclofen.
Baclofen 5 mg: Participants will receive 5mg of baclofen in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
|
Placebo
n=5 Participants
Participants randomized to this arm will receive Placebo.
Placebos: Participants will receive placebo in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
|
|---|---|---|---|
|
Temporal Summation of Pain
|
60.25 units on a scale
Standard Deviation 35.3
|
48.4 units on a scale
Standard Deviation 35.5
|
43.2 units on a scale
Standard Deviation 8.0
|
PRIMARY outcome
Timeframe: 1.5 hours post-drug administration during session 2, occurs 7 ± 2 days after baseline visitPopulation: Data were missing.
Temporal summation of pain refers to a form of endogenous pain facilitation characterized by the perception of increased pain despite constant or even reduced peripheral afferent input. Temporal summation is presumed to be the psychophysical manifestation of wind-up. Wind-up is a phenomenon where repetitive stimulation of C primary afferents at rates greater than 0.3 Hertz produces a slowly increasing response of second-order neurons in the spinal cord. Pain rating scores will be reflected in scores of 0-100, 0 being the least amount of pain and 100 being the most amount of pain.
Outcome measures
| Measure |
Baclofen 10mg
n=3 Participants
Participants randomized to this arm will receive 10 mg of Baclofen.
Baclofen 10mg: Participants will receive 10mg of baclofen in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
|
Baclofen 5mg
n=6 Participants
Participants randomized to this arm will receive 5 mg of Baclofen.
Baclofen 5 mg: Participants will receive 5mg of baclofen in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
|
Placebo
n=5 Participants
Participants randomized to this arm will receive Placebo.
Placebos: Participants will receive placebo in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
|
|---|---|---|---|
|
Temporal Summation of Pain
|
36.7 units on a scale
Standard Deviation 23.6
|
64.5 units on a scale
Standard Deviation 23.0
|
47.6 units on a scale
Standard Deviation 17.5
|
PRIMARY outcome
Timeframe: BaselinePopulation: Data were missing.
A routinely used quantitative sensory testing protocol for the measurement of endogenous pain inhibition is conditioned pain modulation, which refers to the reduction in pain from one stimulus (the test stimulus) produced by the application of a second pain stimulus at a remote body site (the conditioning stimulus). Conditioned pain modulation is believed to reflect the perceptual manifestation of diffuse noxious inhibitory controls, whereby ascending projections from one noxious stimulus activate supraspinal structures that trigger descending inhibitory projections to the dorsal horn. Pain rating scores for the test stimulus and the conditioning stimulus will be reflected in scores of 0-100, 0 being the least amount of pain and 100 being the most amount of pain. The conditioned pain modulation score is the difference between the two pain rating scores.
Outcome measures
| Measure |
Baclofen 10mg
n=5 Participants
Participants randomized to this arm will receive 10 mg of Baclofen.
Baclofen 10mg: Participants will receive 10mg of baclofen in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
|
Baclofen 5mg
n=7 Participants
Participants randomized to this arm will receive 5 mg of Baclofen.
Baclofen 5 mg: Participants will receive 5mg of baclofen in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
|
Placebo
n=6 Participants
Participants randomized to this arm will receive Placebo.
Placebos: Participants will receive placebo in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
|
|---|---|---|---|
|
Conditioned Pain Modulation
|
-2.0 units on a scale
Standard Deviation 5.7
|
2.1 units on a scale
Standard Deviation 15.5
|
-0.2 units on a scale
Standard Deviation 7.4
|
PRIMARY outcome
Timeframe: 1.5 hours post-drug administration during session 2, occurs 7 ± 2 days after baseline visitPopulation: Data were missing.
A routinely used quantitative sensory testing protocol for the measurement of endogenous pain inhibition is conditioned pain modulation, which refers to the reduction in pain from one stimulus (the test stimulus) produced by the application of a second pain stimulus at a remote body site (the conditioning stimulus). Conditioned pain modulation is believed to reflect the perceptual manifestation of diffuse noxious inhibitory controls, whereby ascending projections from one noxious stimulus activate supraspinal structures that trigger descending inhibitory projections to the dorsal horn. Pain rating scores for the test stimulus and the conditioning stimulus will be reflected in scores of 0-100, 0 being the least amount of pain and 100 being the most amount of pain. The conditioned pain modulation score is the difference between the two pain rating scores.
Outcome measures
| Measure |
Baclofen 10mg
n=4 Participants
Participants randomized to this arm will receive 10 mg of Baclofen.
Baclofen 10mg: Participants will receive 10mg of baclofen in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
|
Baclofen 5mg
n=6 Participants
Participants randomized to this arm will receive 5 mg of Baclofen.
Baclofen 5 mg: Participants will receive 5mg of baclofen in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
|
Placebo
n=5 Participants
Participants randomized to this arm will receive Placebo.
Placebos: Participants will receive placebo in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
|
|---|---|---|---|
|
Conditioned Pain Modulation
|
-6.3 units on a scale
Standard Deviation 4.8
|
-10.8 units on a scale
Standard Deviation 15.0
|
3.0 units on a scale
Standard Deviation 5.7
|
PRIMARY outcome
Timeframe: BaselinePopulation: Data were missing.
Ratings of pain in response to discrete stimuli with intensities above the pain threshold detection/ patients provide an intensity rating using any number of a 0-100 scale whereby 0=no pain and 100= the most intense pain imaginable
Outcome measures
| Measure |
Baclofen 10mg
n=5 Participants
Participants randomized to this arm will receive 10 mg of Baclofen.
Baclofen 10mg: Participants will receive 10mg of baclofen in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
|
Baclofen 5mg
n=6 Participants
Participants randomized to this arm will receive 5 mg of Baclofen.
Baclofen 5 mg: Participants will receive 5mg of baclofen in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
|
Placebo
n=6 Participants
Participants randomized to this arm will receive Placebo.
Placebos: Participants will receive placebo in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
|
|---|---|---|---|
|
Suprathreshold Pain Response
|
53.4 units on a scale
Standard Deviation 37.6
|
54.2 units on a scale
Standard Deviation 34.7
|
42.5 units on a scale
Standard Deviation 20.4
|
PRIMARY outcome
Timeframe: 1.5 hours post-drug administration during session 2, occurs 7 ± 2 days after baseline visitPopulation: Data were missing.
Ratings of pain in response to discrete stimuli with intensities above the pain threshold detection/ patients provide an intensity rating using any number of a 0-100 scale whereby 0=no pain and 100= the most intense pain imaginable
Outcome measures
| Measure |
Baclofen 10mg
n=5 Participants
Participants randomized to this arm will receive 10 mg of Baclofen.
Baclofen 10mg: Participants will receive 10mg of baclofen in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
|
Baclofen 5mg
n=8 Participants
Participants randomized to this arm will receive 5 mg of Baclofen.
Baclofen 5 mg: Participants will receive 5mg of baclofen in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
|
Placebo
n=5 Participants
Participants randomized to this arm will receive Placebo.
Placebos: Participants will receive placebo in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
|
|---|---|---|---|
|
Suprathreshold Pain Response
|
54.0 units on a scale
Standard Deviation 30.7
|
68.8 units on a scale
Standard Deviation 20.8
|
36.0 units on a scale
Standard Deviation 15.2
|
SECONDARY outcome
Timeframe: 30 minutes post-drug administration during session 2, occurs 7 ± 2 days after baseline visitMeasures the amount and intensity of side effects after being administered an opioid. The measure consists of 14 questions about potential opioid symptoms, and each the severity of the symptom is rated on a scale from 0 to 4, with 0 reflecting not at all feeling or being bothered by the symptom and 4 reflecting being severely bothered by the symptom. The score is the sum of the 14 responses. The minimum value is 0 and the maximum value is 56.
Outcome measures
| Measure |
Baclofen 10mg
n=5 Participants
Participants randomized to this arm will receive 10 mg of Baclofen.
Baclofen 10mg: Participants will receive 10mg of baclofen in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
|
Baclofen 5mg
n=8 Participants
Participants randomized to this arm will receive 5 mg of Baclofen.
Baclofen 5 mg: Participants will receive 5mg of baclofen in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
|
Placebo
n=6 Participants
Participants randomized to this arm will receive Placebo.
Placebos: Participants will receive placebo in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
|
|---|---|---|---|
|
Opioid Symptom Checklist
|
0.60 units on a scale
Standard Deviation 0.54
|
0.75 units on a scale
Standard Deviation 1.39
|
4.67 units on a scale
Standard Deviation 4.08
|
SECONDARY outcome
Timeframe: 30 minutes post-drug administration during session 2, occurs 7 ± 2 days after baseline visitMeasures subjective and physiological effects of a medication using mood states as well as questions about the dose of medication. The measure consists of 7 questions about potential drug effects, and each response is rated on a scale of 0 to 100, with 0 reflecting not at all feeling the effect and 100 reflecting very much feeling the effect. The score is the sum of the 7 responses. The minimum value is 0 and the maximum value is 700.
Outcome measures
| Measure |
Baclofen 10mg
n=5 Participants
Participants randomized to this arm will receive 10 mg of Baclofen.
Baclofen 10mg: Participants will receive 10mg of baclofen in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
|
Baclofen 5mg
n=8 Participants
Participants randomized to this arm will receive 5 mg of Baclofen.
Baclofen 5 mg: Participants will receive 5mg of baclofen in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
|
Placebo
n=6 Participants
Participants randomized to this arm will receive Placebo.
Placebos: Participants will receive placebo in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
|
|---|---|---|---|
|
26-item Visual Analog Scale (VAS)
|
120.2 units on a scale
Standard Deviation 76.9
|
50.4 units on a scale
Standard Deviation 88.5
|
180.7 units on a scale
Standard Deviation 94.3
|
SECONDARY outcome
Timeframe: 30 minutes post-drug administration during session 2, occurs 7 ± 2 days after baseline visitPopulation: Data were missing.
Measures subjective experiences of a drug. The measure consists of 5 questions about the participant's experience of the drug effects, and each response is rated on a scale of 0 to 100, with 0 reflecting not at all having an experience and 100 reflecting extremely having that experience. The score is the sum of the 5 responses. The minimum value is 0 and the maximum value is 500.
Outcome measures
| Measure |
Baclofen 10mg
n=5 Participants
Participants randomized to this arm will receive 10 mg of Baclofen.
Baclofen 10mg: Participants will receive 10mg of baclofen in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
|
Baclofen 5mg
n=7 Participants
Participants randomized to this arm will receive 5 mg of Baclofen.
Baclofen 5 mg: Participants will receive 5mg of baclofen in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
|
Placebo
n=6 Participants
Participants randomized to this arm will receive Placebo.
Placebos: Participants will receive placebo in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
|
|---|---|---|---|
|
Drug Effects Questionnaire-5
|
103.8 units on a scale
Standard Deviation 65.9
|
101.1 units on a scale
Standard Deviation 76.0
|
168.8 units on a scale
Standard Deviation 106.7
|
SECONDARY outcome
Timeframe: 30 minutes post-drug administration during session 2, occurs 7 ± 2 days after baseline visitThis 26-item VAS measures subjective and physiological effects of a medication using mood states as well as questions about the dose of medication. The measure consists of 7 questions about potential drug effects, and each response is rated on a scale of 0 to 100, with 0 reflecting not at all feeling the effect and 100 reflecting very much feeling the effect. The score is the sum of the 7 responses. The minimum value is 0 and the maximum value is 700.
Outcome measures
| Measure |
Baclofen 10mg
n=5 Participants
Participants randomized to this arm will receive 10 mg of Baclofen.
Baclofen 10mg: Participants will receive 10mg of baclofen in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
|
Baclofen 5mg
n=8 Participants
Participants randomized to this arm will receive 5 mg of Baclofen.
Baclofen 5 mg: Participants will receive 5mg of baclofen in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
|
Placebo
n=6 Participants
Participants randomized to this arm will receive Placebo.
Placebos: Participants will receive placebo in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
|
|---|---|---|---|
|
26-item Visual Analog Scale ("Subjective Drug Effects")
|
120.2 units on a scale
Standard Deviation 76.9
|
50.4 units on a scale
Standard Deviation 88.5
|
180.7 units on a scale
Standard Deviation 94.3
|
Adverse Events
Placebo
Baclofen 5mg
Baclofen 10mg
Serious adverse events
| Measure |
Placebo
n=6 participants at risk
Participants randomized to this arm will receive Placebo.
Placebos: Participants will receive placebo in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
|
Baclofen 5mg
n=8 participants at risk
Participants randomized to this arm will receive 5 mg of Baclofen.
Baclofen 5 mg: Participants will receive 5mg of baclofen in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
|
Baclofen 10mg
n=5 participants at risk
Participants randomized to this arm will receive 10 mg of Baclofen.
Baclofen 10mg: Participants will receive 10mg of baclofen in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
|
|---|---|---|---|
|
Injury, poisoning and procedural complications
Emergency Department Visit
|
16.7%
1/6 • Number of events 1 • From baseline to 48 hours after dose session
|
0.00%
0/8 • From baseline to 48 hours after dose session
|
0.00%
0/5 • From baseline to 48 hours after dose session
|
Other adverse events
| Measure |
Placebo
n=6 participants at risk
Participants randomized to this arm will receive Placebo.
Placebos: Participants will receive placebo in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
|
Baclofen 5mg
n=8 participants at risk
Participants randomized to this arm will receive 5 mg of Baclofen.
Baclofen 5 mg: Participants will receive 5mg of baclofen in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
|
Baclofen 10mg
n=5 participants at risk
Participants randomized to this arm will receive 10 mg of Baclofen.
Baclofen 10mg: Participants will receive 10mg of baclofen in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
|
|---|---|---|---|
|
Injury, poisoning and procedural complications
Buprenorphine Poisoning
|
16.7%
1/6 • Number of events 1 • From baseline to 48 hours after dose session
|
0.00%
0/8 • From baseline to 48 hours after dose session
|
0.00%
0/5 • From baseline to 48 hours after dose session
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place